NIST physical standards for DNA-based medical testing

• Published in: Journal of clinical laboratory analysis Vol. 16; no. 1; pp. 5 - 10
• Main Authors: Barker, Peter E., Watson, Michael S., Ticehurst, John R., Colbert, Jennifer C., O'Connell, Catherine D.
• Format: Journal Article
• Language: English
• Published: New York John Wiley & Sons, Inc 2002
• Subjects: Clinical Laboratory Techniques - standards; diagnostics; DNA; Forensic Medicine - standards; Government Agencies; Humans; Original; Reference Standards; Tandem Repeat Sequences; United States; United States
• ISSN: 0887-8013; 1098-2825
• DOI: 10.1002/jcla.2062

As DNA and RNA become major targets for clinical laboratory analysis, benchmark reagents will play an increasingly important role in standardization. Reliable national and international nucleic acid standards promote automation and third‐party reimbursement for clinical testing. Furthermore, nucleic acid standards provide materials for quality assurance and quality control (QA/QC), and proficiency testing. Standard methods and training initially evolved from consensus guidelines endorsed by professional societies and governmental agencies. The National Institute of Standards and Technology (NIST), a nonregulatory agency of the U.S. Department of Commerce, develops and certifies physical and chemical standards in support of national commerce, manufacturing, and science. In its role supporting U.S. science and industry, the NIST responds to specific standards needs, most recently for medically and biologically important analytes. Broad‐based consensus developed through interdisciplinary NIST workshops initiated development of NIST‐certified DNA standards. Such materials serve the diagnostic community and help manufacturers benchmark a variety of DNA diagnostic testing platforms. Here we summarize the NIST experience and programs for development of national standards for DNA‐based medical diagnostic testing. J. Clin. Lab. Anal. 16:5–10, 2002. © 2002 Wiley‐Liss, Inc.